| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Urinary Bladder Neoplasms | 43 | 2025 | 509 | 3.940 |
Why?
|
| Carcinoma, Renal Cell | 19 | 2022 | 235 | 2.400 |
Why?
|
| Carcinoma, Transitional Cell | 19 | 2025 | 179 | 2.350 |
Why?
|
| Prostatic Neoplasms | 27 | 2023 | 1386 | 2.050 |
Why?
|
| Bipolar Disorder | 5 | 2025 | 354 | 1.890 |
Why?
|
| Antibodies, Monoclonal, Humanized | 8 | 2024 | 542 | 1.740 |
Why?
|
| Kidney Neoplasms | 17 | 2022 | 439 | 1.730 |
Why?
|
| STAT3 Transcription Factor | 2 | 2024 | 215 | 1.450 |
Why?
|
| Depressive Disorder, Major | 4 | 2023 | 424 | 1.370 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 23 | 2023 | 1306 | 1.270 |
Why?
|
| B-Lymphocyte Subsets | 2 | 2019 | 23 | 1.240 |
Why?
|
| Urothelium | 6 | 2025 | 60 | 1.200 |
Why?
|
| DNA, Mitochondrial | 3 | 2023 | 231 | 1.170 |
Why?
|
| Brain-Computer Interfaces | 2 | 2020 | 16 | 1.090 |
Why?
|
| Middle Aged | 110 | 2025 | 27322 | 0.960 |
Why?
|
| Amyotrophic Lateral Sclerosis | 2 | 2020 | 173 | 0.940 |
Why?
|
| Polycomb Repressive Complex 2 | 1 | 2025 | 27 | 0.930 |
Why?
|
| Aged | 95 | 2025 | 20022 | 0.920 |
Why?
|
| Humans | 213 | 2025 | 125883 | 0.890 |
Why?
|
| Interferon-gamma | 3 | 2024 | 518 | 0.890 |
Why?
|
| Carcinoma in Situ | 1 | 2025 | 72 | 0.890 |
Why?
|
| Lymphocytes | 3 | 2022 | 354 | 0.880 |
Why?
|
| Male | 166 | 2025 | 62056 | 0.870 |
Why?
|
| Lymphokines | 2 | 2023 | 66 | 0.850 |
Why?
|
| Biomarkers | 8 | 2021 | 3139 | 0.830 |
Why?
|
| Genes, Mitochondrial | 1 | 2023 | 22 | 0.810 |
Why?
|
| Platelet-Derived Growth Factor | 1 | 2023 | 42 | 0.810 |
Why?
|
| Mitochondria | 3 | 2025 | 720 | 0.790 |
Why?
|
| Urologic Neoplasms | 7 | 2024 | 37 | 0.780 |
Why?
|
| Hemoglobinuria, Paroxysmal | 2 | 2019 | 25 | 0.760 |
Why?
|
| Biomarkers, Tumor | 10 | 2025 | 1570 | 0.760 |
Why?
|
| Apoptosis | 5 | 2024 | 1801 | 0.750 |
Why?
|
| Hernia, Inguinal | 3 | 2023 | 41 | 0.750 |
Why?
|
| Hemophilia A | 2 | 2019 | 24 | 0.750 |
Why?
|
| Reactive Oxygen Species | 1 | 2025 | 488 | 0.750 |
Why?
|
| Androgen Antagonists | 5 | 2009 | 104 | 0.740 |
Why?
|
| Fatty Acids, Monounsaturated | 2 | 2021 | 49 | 0.730 |
Why?
|
| Nephrectomy | 8 | 2020 | 172 | 0.720 |
Why?
|
| Proctitis | 1 | 2021 | 6 | 0.720 |
Why?
|
| Testicular Neoplasms | 11 | 2012 | 121 | 0.700 |
Why?
|
| Receptors, Androgen | 5 | 2009 | 398 | 0.700 |
Why?
|
| Aged, 80 and over | 41 | 2025 | 6571 | 0.700 |
Why?
|
| Neoplasms, Radiation-Induced | 1 | 2021 | 75 | 0.690 |
Why?
|
| Spermatic Cord | 4 | 2015 | 12 | 0.680 |
Why?
|
| Radiation Injuries | 1 | 2021 | 137 | 0.650 |
Why?
|
| Hematoma | 2 | 2019 | 84 | 0.640 |
Why?
|
| Schizophrenia | 3 | 2018 | 323 | 0.630 |
Why?
|
| Prostatectomy | 4 | 2023 | 309 | 0.630 |
Why?
|
| Leukemia, Myeloid, Acute | 3 | 2025 | 555 | 0.620 |
Why?
|
| Tongue Diseases | 1 | 2019 | 11 | 0.620 |
Why?
|
| Minimally Invasive Surgical Procedures | 6 | 2010 | 191 | 0.620 |
Why?
|
| Blood Platelets | 1 | 2022 | 312 | 0.610 |
Why?
|
| Endoscopy | 7 | 2010 | 281 | 0.590 |
Why?
|
| Female | 104 | 2025 | 67886 | 0.590 |
Why?
|
| Interleukin-2 Receptor alpha Subunit | 1 | 2018 | 51 | 0.580 |
Why?
|
| Cell Lineage | 2 | 2019 | 326 | 0.570 |
Why?
|
| Transcription Factors | 14 | 2025 | 2348 | 0.570 |
Why?
|
| Hemorrhage | 3 | 2019 | 467 | 0.560 |
Why?
|
| Adrenalectomy | 5 | 2010 | 40 | 0.560 |
Why?
|
| Colorectal Neoplasms | 2 | 2021 | 621 | 0.540 |
Why?
|
| Depression | 3 | 2023 | 1283 | 0.540 |
Why?
|
| Neurodegenerative Diseases | 1 | 2020 | 270 | 0.530 |
Why?
|
| Testis | 11 | 2005 | 406 | 0.520 |
Why?
|
| Japan | 8 | 2025 | 171 | 0.520 |
Why?
|
| Membrane Proteins | 6 | 2019 | 1548 | 0.510 |
Why?
|
| Hematopoietic Stem Cells | 2 | 2024 | 499 | 0.510 |
Why?
|
| DNA-Binding Proteins | 10 | 2024 | 1879 | 0.500 |
Why?
|
| Adult | 66 | 2025 | 30246 | 0.500 |
Why?
|
| Cystectomy | 13 | 2016 | 157 | 0.490 |
Why?
|
| Cytokines | 3 | 2022 | 1316 | 0.490 |
Why?
|
| Prophylactic Surgical Procedures | 1 | 2015 | 3 | 0.480 |
Why?
|
| Inguinal Canal | 1 | 2015 | 12 | 0.470 |
Why?
|
| Cisplatin | 15 | 2012 | 270 | 0.470 |
Why?
|
| Aquaporins | 6 | 2004 | 16 | 0.460 |
Why?
|
| Prognosis | 18 | 2024 | 4691 | 0.460 |
Why?
|
| Biopsy, Needle | 5 | 2013 | 215 | 0.460 |
Why?
|
| Drosophila Proteins | 4 | 2010 | 748 | 0.430 |
Why?
|
| Transcription, Genetic | 8 | 2010 | 1381 | 0.420 |
Why?
|
| Prostate-Specific Antigen | 9 | 2016 | 233 | 0.410 |
Why?
|
| Cell Line, Tumor | 9 | 2025 | 3465 | 0.400 |
Why?
|
| Adenocarcinoma | 10 | 2008 | 975 | 0.390 |
Why?
|
| C-Reactive Protein | 4 | 2021 | 437 | 0.390 |
Why?
|
| Laparotomy | 3 | 2002 | 143 | 0.390 |
Why?
|
| Antineoplastic Agents, Immunological | 3 | 2024 | 121 | 0.380 |
Why?
|
| Animals | 50 | 2025 | 33175 | 0.370 |
Why?
|
| Flutamide | 2 | 2009 | 27 | 0.370 |
Why?
|
| Motor Cortex | 3 | 2017 | 74 | 0.370 |
Why?
|
| Ion Channels | 5 | 2001 | 200 | 0.360 |
Why?
|
| Neoplasm Staging | 21 | 2020 | 1295 | 0.350 |
Why?
|
| Immunohistochemistry | 12 | 2025 | 1601 | 0.350 |
Why?
|
| Retrospective Studies | 21 | 2024 | 16775 | 0.340 |
Why?
|
| Lithotripsy | 7 | 1994 | 25 | 0.340 |
Why?
|
| Adrenocorticotropic Hormone | 3 | 2002 | 63 | 0.330 |
Why?
|
| Immunoconjugates | 5 | 2018 | 48 | 0.330 |
Why?
|
| Retroperitoneal Neoplasms | 3 | 2010 | 31 | 0.330 |
Why?
|
| Adrenal Gland Diseases | 3 | 2004 | 16 | 0.330 |
Why?
|
| Communication | 1 | 2014 | 511 | 0.320 |
Why?
|
| Gene Expression Regulation, Developmental | 4 | 2010 | 974 | 0.320 |
Why?
|
| Synovial Fluid | 2 | 2000 | 17 | 0.320 |
Why?
|
| Embryo, Nonmammalian | 1 | 2010 | 137 | 0.320 |
Why?
|
| Treatment Outcome | 28 | 2022 | 12354 | 0.320 |
Why?
|
| Glucocorticoids | 7 | 2006 | 354 | 0.320 |
Why?
|
| Brain Neoplasms | 4 | 2022 | 1217 | 0.310 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 3 | 2022 | 148 | 0.310 |
Why?
|
| Pneumonectomy | 4 | 2000 | 145 | 0.310 |
Why?
|
| Arthritis | 2 | 2000 | 83 | 0.300 |
Why?
|
| Neoplasms, Germ Cell and Embryonal | 4 | 2012 | 85 | 0.300 |
Why?
|
| Fascia Lata | 2 | 1999 | 3 | 0.300 |
Why?
|
| Kidney Diseases | 3 | 2004 | 468 | 0.300 |
Why?
|
| Urinary Bladder | 6 | 2023 | 248 | 0.290 |
Why?
|
| Neoplasms, Hormone-Dependent | 3 | 2008 | 92 | 0.290 |
Why?
|
| Cell Differentiation | 6 | 2024 | 1850 | 0.290 |
Why?
|
| Antineoplastic Agents | 11 | 2012 | 1750 | 0.290 |
Why?
|
| Combined Modality Therapy | 16 | 2020 | 1237 | 0.280 |
Why?
|
| Neoplasm Recurrence, Local | 8 | 2021 | 1236 | 0.270 |
Why?
|
| Vascular Endothelial Growth Factor A | 4 | 2006 | 426 | 0.270 |
Why?
|
| Drosophila melanogaster | 3 | 2010 | 822 | 0.270 |
Why?
|
| Trans-Activators | 8 | 2004 | 672 | 0.270 |
Why?
|
| Dendritic Cells | 2 | 2022 | 435 | 0.260 |
Why?
|
| Peptides | 2 | 2010 | 826 | 0.260 |
Why?
|
| Response Elements | 2 | 2013 | 101 | 0.260 |
Why?
|
| Pilot Projects | 3 | 2021 | 1382 | 0.260 |
Why?
|
| Antineoplastic Agents, Hormonal | 2 | 2007 | 253 | 0.250 |
Why?
|
| Diagnosis, Differential | 8 | 2025 | 1819 | 0.250 |
Why?
|
| Transcranial Magnetic Stimulation | 2 | 2017 | 76 | 0.250 |
Why?
|
| Neoplasm Invasiveness | 11 | 2008 | 636 | 0.250 |
Why?
|
| Graft Rejection | 3 | 2000 | 554 | 0.250 |
Why?
|
| Gene Expression | 4 | 2004 | 1489 | 0.250 |
Why?
|
| Monocytes | 2 | 2019 | 329 | 0.250 |
Why?
|
| B7-H1 Antigen | 2 | 2024 | 125 | 0.250 |
Why?
|
| Tumor Cells, Cultured | 17 | 2006 | 993 | 0.240 |
Why?
|
| Nylons | 1 | 2006 | 13 | 0.240 |
Why?
|
| Proto-Oncogene Proteins | 3 | 2025 | 586 | 0.240 |
Why?
|
| Recombinant Proteins | 7 | 2019 | 1294 | 0.240 |
Why?
|
| Government Employees | 1 | 2025 | 2 | 0.230 |
Why?
|
| Seminoma | 4 | 2009 | 9 | 0.230 |
Why?
|
| Sick Leave | 1 | 2025 | 3 | 0.230 |
Why?
|
| Membrane Glycoproteins | 5 | 2006 | 409 | 0.230 |
Why?
|
| Robotic Surgical Procedures | 2 | 2023 | 221 | 0.230 |
Why?
|
| Occupational Stress | 1 | 2025 | 13 | 0.230 |
Why?
|
| Enhancer of Zeste Homolog 2 Protein | 1 | 2025 | 65 | 0.230 |
Why?
|
| Genes, Insect | 4 | 2010 | 121 | 0.230 |
Why?
|
| Oculomotor Nerve | 1 | 2024 | 5 | 0.230 |
Why?
|
| Posterior Cerebral Artery | 1 | 2024 | 5 | 0.220 |
Why?
|
| Hemopneumothorax | 1 | 2004 | 2 | 0.220 |
Why?
|
| Nerve Compression Syndromes | 1 | 2024 | 14 | 0.220 |
Why?
|
| Oculomotor Nerve Diseases | 1 | 2024 | 11 | 0.220 |
Why?
|
| Metabolome | 2 | 2018 | 318 | 0.220 |
Why?
|
| Myeloid-Lymphoid Leukemia Protein | 1 | 2025 | 74 | 0.220 |
Why?
|
| Adrenal Glands | 3 | 2002 | 48 | 0.220 |
Why?
|
| Workplace | 1 | 2025 | 74 | 0.220 |
Why?
|
| Pupil | 1 | 2024 | 45 | 0.220 |
Why?
|
| Lung Neoplasms | 7 | 2016 | 1488 | 0.220 |
Why?
|
| Dosage Compensation, Genetic | 2 | 2001 | 58 | 0.220 |
Why?
|
| Retroperitoneal Space | 2 | 2019 | 20 | 0.210 |
Why?
|
| Doxorubicin | 6 | 2020 | 288 | 0.210 |
Why?
|
| Histone-Lysine N-Methyltransferase | 1 | 2025 | 154 | 0.210 |
Why?
|
| Proline | 1 | 2004 | 74 | 0.210 |
Why?
|
| Genital Neoplasms, Male | 3 | 2004 | 12 | 0.210 |
Why?
|
| Rats | 17 | 2018 | 3390 | 0.200 |
Why?
|
| Dioxygenases | 1 | 2024 | 65 | 0.200 |
Why?
|
| Hydrocortisone | 2 | 2002 | 221 | 0.200 |
Why?
|
| Dexamethasone | 6 | 2018 | 263 | 0.200 |
Why?
|
| Calcium Signaling | 1 | 2025 | 240 | 0.200 |
Why?
|
| Leucine | 1 | 2004 | 255 | 0.200 |
Why?
|
| Purpura, Thrombocytopenic, Idiopathic | 1 | 2023 | 52 | 0.200 |
Why?
|
| Germinoma | 2 | 2004 | 30 | 0.200 |
Why?
|
| Cell-Free Nucleic Acids | 1 | 2023 | 51 | 0.200 |
Why?
|
| Lymphocyte Function-Associated Antigen-1 | 1 | 2022 | 26 | 0.190 |
Why?
|
| Ipilimumab | 1 | 2022 | 58 | 0.190 |
Why?
|
| Surveys and Questionnaires | 4 | 2025 | 3886 | 0.190 |
Why?
|
| Gilbert Disease | 1 | 2022 | 5 | 0.190 |
Why?
|
| Spherocytosis, Hereditary | 1 | 2022 | 7 | 0.190 |
Why?
|
| Chromosomal Proteins, Non-Histone | 2 | 2001 | 198 | 0.190 |
Why?
|
| Gene Expression Regulation, Neoplastic | 6 | 2018 | 1931 | 0.190 |
Why?
|
| Adrenal Gland Neoplasms | 3 | 2010 | 77 | 0.190 |
Why?
|
| Picibanil | 1 | 2002 | 4 | 0.190 |
Why?
|
| Awards and Prizes | 1 | 2023 | 64 | 0.190 |
Why?
|
| Parkinson Disease | 2 | 2017 | 714 | 0.180 |
Why?
|
| Mice | 16 | 2025 | 17578 | 0.180 |
Why?
|
| Prostatic Neoplasms, Castration-Resistant | 1 | 2023 | 85 | 0.180 |
Why?
|
| Leukemia, Promyelocytic, Acute | 1 | 2022 | 23 | 0.180 |
Why?
|
| Neurilemmoma | 1 | 2002 | 40 | 0.180 |
Why?
|
| Multivariate Analysis | 8 | 2015 | 1348 | 0.180 |
Why?
|
| Transfection | 9 | 2013 | 949 | 0.180 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2022 | 69 | 0.180 |
Why?
|
| Lymphocyte Count | 1 | 2022 | 116 | 0.180 |
Why?
|
| Postoperative Care | 2 | 2020 | 303 | 0.180 |
Why?
|
| Platelet Count | 1 | 2022 | 129 | 0.180 |
Why?
|
| Prostate | 3 | 2023 | 405 | 0.180 |
Why?
|
| Antigens, CD34 | 2 | 2018 | 99 | 0.180 |
Why?
|
| Magnetic Resonance Imaging | 10 | 2013 | 3571 | 0.180 |
Why?
|
| Mediastinal Neoplasms | 3 | 2010 | 38 | 0.180 |
Why?
|
| Heart Transplantation | 2 | 1998 | 857 | 0.180 |
Why?
|
| Thrombocytopenia | 1 | 2023 | 223 | 0.180 |
Why?
|
| Tumor Microenvironment | 2 | 2023 | 622 | 0.180 |
Why?
|
| Hormone Replacement Therapy | 2 | 2002 | 209 | 0.180 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2022 | 162 | 0.180 |
Why?
|
| Robotics | 1 | 2023 | 107 | 0.180 |
Why?
|
| Rats, Inbred Lew | 10 | 2005 | 64 | 0.180 |
Why?
|
| Ascites | 1 | 2002 | 98 | 0.180 |
Why?
|
| Transplantation, Homologous | 7 | 2003 | 639 | 0.180 |
Why?
|
| Bone Marrow Cells | 2 | 2019 | 236 | 0.170 |
Why?
|
| Diuresis | 1 | 2000 | 45 | 0.170 |
Why?
|
| Urinary Calculi | 2 | 1990 | 18 | 0.170 |
Why?
|
| Neoplastic Stem Cells | 2 | 2025 | 329 | 0.170 |
Why?
|
| Muscle Neoplasms | 1 | 2000 | 22 | 0.170 |
Why?
|
| Intestinal Neoplasms | 1 | 2021 | 37 | 0.170 |
Why?
|
| Neoadjuvant Therapy | 2 | 2006 | 377 | 0.170 |
Why?
|
| Cord Blood Stem Cell Transplantation | 1 | 2021 | 52 | 0.170 |
Why?
|
| Hemangioma, Cavernous | 1 | 2000 | 18 | 0.170 |
Why?
|
| Molecular Sequence Data | 9 | 2006 | 3600 | 0.170 |
Why?
|
| Lymphoma, T-Cell | 1 | 2021 | 61 | 0.170 |
Why?
|
| Oxidative Stress | 1 | 2025 | 752 | 0.160 |
Why?
|
| Phenotype | 3 | 2019 | 4298 | 0.160 |
Why?
|
| Chorea | 1 | 2000 | 37 | 0.160 |
Why?
|
| Liver Diseases | 1 | 2004 | 377 | 0.160 |
Why?
|
| Interleukin-16 | 1 | 2000 | 1 | 0.160 |
Why?
|
| Anemia | 1 | 2024 | 330 | 0.160 |
Why?
|
| Rheumatoid Factor | 1 | 2000 | 6 | 0.160 |
Why?
|
| Immunoglobulin Isotypes | 1 | 2000 | 15 | 0.160 |
Why?
|
| Receptors, Cytoplasmic and Nuclear | 3 | 2002 | 312 | 0.160 |
Why?
|
| Matrix Metalloproteinase 3 | 1 | 2000 | 17 | 0.160 |
Why?
|
| Energy Metabolism | 1 | 2025 | 761 | 0.160 |
Why?
|
| Surgery, Computer-Assisted | 2 | 2015 | 66 | 0.160 |
Why?
|
| Tissue Inhibitor of Metalloproteinases | 1 | 2000 | 20 | 0.160 |
Why?
|
| Genes, abl | 1 | 2019 | 7 | 0.160 |
Why?
|
| Hypothyroidism | 1 | 2000 | 78 | 0.160 |
Why?
|
| Chemoradiotherapy | 1 | 2020 | 117 | 0.160 |
Why?
|
| Remission Induction | 6 | 2022 | 298 | 0.160 |
Why?
|
| Interleukin-6 | 1 | 2021 | 405 | 0.160 |
Why?
|
| DNA Helicases | 1 | 2001 | 229 | 0.160 |
Why?
|
| Cells, Cultured | 7 | 2018 | 2902 | 0.160 |
Why?
|
| Gene Expression Regulation | 4 | 2004 | 2330 | 0.160 |
Why?
|
| Factor VIIa | 1 | 2019 | 22 | 0.160 |
Why?
|
| Muscular Diseases | 1 | 2000 | 114 | 0.150 |
Why?
|
| Hernia, Diaphragmatic | 1 | 2000 | 98 | 0.150 |
Why?
|
| Glycosylphosphatidylinositols | 1 | 2019 | 16 | 0.150 |
Why?
|
| Tissue Inhibitor of Metalloproteinase-1 | 1 | 2019 | 38 | 0.150 |
Why?
|
| Receptors, CCR2 | 1 | 2019 | 23 | 0.150 |
Why?
|
| RNA, Messenger | 11 | 2004 | 2551 | 0.150 |
Why?
|
| Arthritis, Rheumatoid | 5 | 2006 | 282 | 0.150 |
Why?
|
| Young Adult | 8 | 2018 | 9583 | 0.150 |
Why?
|
| Renal Dialysis | 2 | 2007 | 902 | 0.150 |
Why?
|
| Mice, Transgenic | 3 | 2019 | 2317 | 0.150 |
Why?
|
| Body Mass Index | 3 | 2015 | 1640 | 0.150 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 2019 | 101 | 0.150 |
Why?
|
| Heterografts | 1 | 2019 | 189 | 0.150 |
Why?
|
| Neoplasm Transplantation | 3 | 2018 | 359 | 0.150 |
Why?
|
| Colonic Diseases | 1 | 2019 | 37 | 0.150 |
Why?
|
| Colonoscopy | 1 | 2021 | 243 | 0.150 |
Why?
|
| Base Sequence | 10 | 2006 | 2772 | 0.150 |
Why?
|
| Survival Analysis | 8 | 2021 | 1473 | 0.150 |
Why?
|
| Telomere | 2 | 1997 | 210 | 0.150 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 4 | 2013 | 98 | 0.150 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 8 | 2007 | 1236 | 0.150 |
Why?
|
| Omentum | 2 | 2000 | 41 | 0.150 |
Why?
|
| Cysts | 2 | 2006 | 92 | 0.150 |
Why?
|
| Adrenal Hyperplasia, Congenital | 2 | 1996 | 34 | 0.150 |
Why?
|
| Pericardiectomy | 1 | 1998 | 10 | 0.150 |
Why?
|
| Fetal Blood | 1 | 2019 | 171 | 0.150 |
Why?
|
| Receptors, Interferon | 1 | 1998 | 21 | 0.150 |
Why?
|
| Signal Transduction | 6 | 2023 | 4463 | 0.150 |
Why?
|
| Chromatin | 2 | 2001 | 488 | 0.150 |
Why?
|
| Cardiomyopathy, Dilated | 1 | 2000 | 208 | 0.150 |
Why?
|
| Telomerase | 3 | 2004 | 153 | 0.150 |
Why?
|
| Antibodies, Bispecific | 1 | 2019 | 51 | 0.150 |
Why?
|
| Feasibility Studies | 5 | 2007 | 786 | 0.140 |
Why?
|
| Hodgkin Disease | 2 | 2018 | 291 | 0.140 |
Why?
|
| Arthritis, Experimental | 1 | 1998 | 21 | 0.140 |
Why?
|
| Sutures | 1 | 1999 | 62 | 0.140 |
Why?
|
| Neoplasms, Second Primary | 3 | 2008 | 142 | 0.140 |
Why?
|
| Bone Marrow Neoplasms | 1 | 2018 | 23 | 0.140 |
Why?
|
| Neoplastic Cells, Circulating | 3 | 2006 | 76 | 0.140 |
Why?
|
| Autoimmune Diseases | 1 | 2000 | 266 | 0.140 |
Why?
|
| Cortisone | 1 | 2018 | 10 | 0.140 |
Why?
|
| Vasopressins | 2 | 2013 | 44 | 0.140 |
Why?
|
| Arachnoid | 1 | 1998 | 9 | 0.140 |
Why?
|
| Kidney Pelvis | 4 | 2004 | 43 | 0.140 |
Why?
|
| Spinal Nerve Roots | 1 | 1998 | 17 | 0.140 |
Why?
|
| Motivation | 1 | 2020 | 323 | 0.140 |
Why?
|
| Cyclic GMP | 1 | 2018 | 89 | 0.140 |
Why?
|
| Diaphragm | 1 | 1999 | 102 | 0.140 |
Why?
|
| Ossification, Heterotopic | 1 | 1998 | 37 | 0.140 |
Why?
|
| Androgen Receptor Antagonists | 2 | 2008 | 40 | 0.140 |
Why?
|
| Pleural Neoplasms | 1 | 1999 | 72 | 0.140 |
Why?
|
| Early Detection of Cancer | 1 | 2021 | 398 | 0.140 |
Why?
|
| Chemokine CXCL12 | 1 | 2017 | 34 | 0.140 |
Why?
|
| Thoracoscopy | 3 | 2004 | 43 | 0.130 |
Why?
|
| Sympathetic Nervous System | 3 | 2003 | 55 | 0.130 |
Why?
|
| Radiotherapy, Adjuvant | 2 | 2016 | 153 | 0.130 |
Why?
|
| Spermatozoa | 3 | 2004 | 238 | 0.130 |
Why?
|
| Abscess | 1 | 1999 | 141 | 0.130 |
Why?
|
| Pericardium | 1 | 1998 | 101 | 0.130 |
Why?
|
| Kidney Calculi | 4 | 1991 | 44 | 0.130 |
Why?
|
| Mesothelioma | 1 | 1999 | 90 | 0.130 |
Why?
|
| Mental Disorders | 1 | 2025 | 853 | 0.130 |
Why?
|
| Retinal Necrosis Syndrome, Acute | 1 | 2017 | 2 | 0.130 |
Why?
|
| Gelatinases | 1 | 1997 | 16 | 0.130 |
Why?
|
| Collagenases | 1 | 1997 | 16 | 0.130 |
Why?
|
| Androgens | 3 | 2009 | 267 | 0.130 |
Why?
|
| Receptors, CXCR4 | 1 | 2017 | 65 | 0.130 |
Why?
|
| Electrophoresis, Capillary | 1 | 2016 | 11 | 0.130 |
Why?
|
| Psychotropic Drugs | 1 | 2018 | 122 | 0.130 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 1998 | 222 | 0.130 |
Why?
|
| Severity of Illness Index | 5 | 2014 | 2917 | 0.130 |
Why?
|
| Immunity, Innate | 1 | 2019 | 394 | 0.130 |
Why?
|
| Mycobacterium bovis | 1 | 1997 | 32 | 0.130 |
Why?
|
| Carboplatin | 3 | 2018 | 82 | 0.130 |
Why?
|
| Collagen | 1 | 1998 | 294 | 0.130 |
Why?
|
| DNA, Complementary | 4 | 2001 | 435 | 0.130 |
Why?
|
| Immunoassay | 1 | 2017 | 125 | 0.130 |
Why?
|
| Pneumothorax | 1 | 1997 | 81 | 0.130 |
Why?
|
| Etoposide | 6 | 2018 | 112 | 0.130 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2019 | 480 | 0.130 |
Why?
|
| Metalloendopeptidases | 1 | 1997 | 99 | 0.130 |
Why?
|
| Phosphoproteins | 3 | 2003 | 421 | 0.130 |
Why?
|
| Repressor Proteins | 1 | 2001 | 765 | 0.130 |
Why?
|
| MicroRNAs | 1 | 2023 | 871 | 0.130 |
Why?
|
| Lupus Erythematosus, Systemic | 1 | 2019 | 219 | 0.130 |
Why?
|
| Colon | 1 | 2019 | 354 | 0.130 |
Why?
|
| Histiocytosis | 1 | 2016 | 18 | 0.130 |
Why?
|
| Neuralgia | 1 | 2017 | 49 | 0.120 |
Why?
|
| Rats, Inbred Strains | 7 | 2003 | 199 | 0.120 |
Why?
|
| Sagittal Sinus Thrombosis | 1 | 2016 | 4 | 0.120 |
Why?
|
| Bone Neoplasms | 3 | 1997 | 425 | 0.120 |
Why?
|
| Laparoscopy | 1 | 2002 | 516 | 0.120 |
Why?
|
| Graft Survival | 4 | 2003 | 453 | 0.120 |
Why?
|
| Paresis | 1 | 2016 | 34 | 0.120 |
Why?
|
| DNA Copy Number Variations | 1 | 2021 | 1004 | 0.120 |
Why?
|
| Genes, p53 | 1 | 1997 | 213 | 0.120 |
Why?
|
| Ureteral Neoplasms | 3 | 2008 | 25 | 0.120 |
Why?
|
| Cytotoxicity, Immunologic | 1 | 1997 | 258 | 0.120 |
Why?
|
| Transcranial Direct Current Stimulation | 1 | 2016 | 22 | 0.120 |
Why?
|
| Recurrence | 5 | 2020 | 1408 | 0.120 |
Why?
|
| Intraoperative Period | 1 | 2016 | 65 | 0.120 |
Why?
|
| Cytarabine | 1 | 2016 | 99 | 0.120 |
Why?
|
| Urethral Neoplasms | 2 | 2008 | 9 | 0.120 |
Why?
|
| Lymphoma, B-Cell, Marginal Zone | 1 | 2016 | 59 | 0.120 |
Why?
|
| Dementia | 1 | 2000 | 400 | 0.120 |
Why?
|
| Genes, Wilms Tumor | 1 | 1995 | 5 | 0.120 |
Why?
|
| Protein Precursors | 2 | 2013 | 140 | 0.120 |
Why?
|
| Natriuretic Peptide, Brain | 1 | 2018 | 276 | 0.120 |
Why?
|
| Upper Extremity | 1 | 2016 | 52 | 0.120 |
Why?
|
| Chlormadinone Acetate | 1 | 1995 | 1 | 0.120 |
Why?
|
| Progesterone Congeners | 1 | 1995 | 5 | 0.120 |
Why?
|
| Virilism | 1 | 1995 | 14 | 0.120 |
Why?
|
| Cell Transformation, Neoplastic | 3 | 2004 | 605 | 0.120 |
Why?
|
| Prefrontal Cortex | 1 | 2017 | 206 | 0.120 |
Why?
|
| Stroke Rehabilitation | 1 | 2016 | 64 | 0.120 |
Why?
|
| Point Mutation | 1 | 1997 | 337 | 0.120 |
Why?
|
| Protein Processing, Post-Translational | 2 | 2010 | 348 | 0.120 |
Why?
|
| Peritoneum | 1 | 2015 | 38 | 0.120 |
Why?
|
| Matrix Metalloproteinase 9 | 3 | 2002 | 126 | 0.120 |
Why?
|
| Surgical Equipment | 1 | 2015 | 5 | 0.120 |
Why?
|
| Ureteral Calculi | 5 | 1994 | 13 | 0.120 |
Why?
|
| Mass Spectrometry | 1 | 2016 | 350 | 0.110 |
Why?
|
| Kidney | 3 | 1991 | 1261 | 0.110 |
Why?
|
| Lower Extremity | 1 | 2017 | 180 | 0.110 |
Why?
|
| Teratoma | 2 | 2009 | 121 | 0.110 |
Why?
|
| Glycyrrhetinic Acid | 1 | 1994 | 1 | 0.110 |
Why?
|
| Lymphatic Metastasis | 5 | 2011 | 425 | 0.110 |
Why?
|
| Antiviral Agents | 2 | 2017 | 777 | 0.110 |
Why?
|
| Bone Density | 4 | 2002 | 351 | 0.110 |
Why?
|
| Drug Administration Schedule | 7 | 2007 | 734 | 0.110 |
Why?
|
| Vitellogenins | 1 | 1994 | 8 | 0.110 |
Why?
|
| Orchiectomy | 4 | 2004 | 53 | 0.110 |
Why?
|
| B-Lymphocytes | 1 | 2017 | 514 | 0.110 |
Why?
|
| Hymenoptera | 1 | 1994 | 8 | 0.110 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 2 | 2019 | 1158 | 0.110 |
Why?
|
| Central Nervous System | 3 | 2022 | 272 | 0.110 |
Why?
|
| Hyponatremia | 2 | 2000 | 70 | 0.110 |
Why?
|
| Hypertension | 4 | 1995 | 1281 | 0.110 |
Why?
|
| Lung Transplantation | 3 | 2003 | 342 | 0.110 |
Why?
|
| Genes, Tumor Suppressor | 4 | 2009 | 200 | 0.110 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 5 | 2004 | 781 | 0.110 |
Why?
|
| Time Factors | 11 | 2020 | 6024 | 0.100 |
Why?
|
| Sorption Detoxification | 1 | 2013 | 2 | 0.100 |
Why?
|
| Basic Helix-Loop-Helix Transcription Factors | 5 | 2013 | 361 | 0.100 |
Why?
|
| Insect Proteins | 3 | 1999 | 106 | 0.100 |
Why?
|
| Equipment Design | 4 | 2015 | 582 | 0.100 |
Why?
|
| Protein Isoforms | 3 | 2010 | 403 | 0.100 |
Why?
|
| Nuclear Proteins | 4 | 2004 | 1211 | 0.100 |
Why?
|
| Neoplasm Metastasis | 5 | 2021 | 681 | 0.100 |
Why?
|
| Neurophysins | 1 | 2013 | 4 | 0.100 |
Why?
|
| Survival Rate | 6 | 2008 | 2054 | 0.100 |
Why?
|
| Postoperative Complications | 7 | 2023 | 2978 | 0.100 |
Why?
|
| Cytoskeletal Proteins | 3 | 2022 | 274 | 0.100 |
Why?
|
| Posterior Leukoencephalopathy Syndrome | 1 | 2013 | 18 | 0.100 |
Why?
|
| Testosterone | 3 | 2007 | 600 | 0.100 |
Why?
|
| Motor Activity | 1 | 2016 | 504 | 0.100 |
Why?
|
| Propylene Glycols | 2 | 2003 | 19 | 0.100 |
Why?
|
| Acetylglucosaminidase | 2 | 1990 | 12 | 0.100 |
Why?
|
| Ifosfamide | 5 | 2018 | 30 | 0.100 |
Why?
|
| Neoplasm Proteins | 3 | 2006 | 661 | 0.100 |
Why?
|
| Neovascularization, Pathologic | 2 | 2006 | 236 | 0.100 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2015 | 376 | 0.090 |
Why?
|
| Tomography, X-Ray Computed | 9 | 2016 | 1991 | 0.090 |
Why?
|
| Perineum | 3 | 2012 | 47 | 0.090 |
Why?
|
| T-Lymphocytes | 2 | 2017 | 1703 | 0.090 |
Why?
|
| Nephrostomy, Percutaneous | 2 | 2008 | 19 | 0.090 |
Why?
|
| Adolescent | 12 | 2016 | 19934 | 0.090 |
Why?
|
| Shock, Septic | 1 | 2013 | 147 | 0.090 |
Why?
|
| Spermatogenesis | 3 | 2001 | 169 | 0.090 |
Why?
|
| Pregnancy | 2 | 2023 | 7392 | 0.090 |
Why?
|
| Tracheostomy | 1 | 2014 | 214 | 0.090 |
Why?
|
| Radiotherapy Dosage | 2 | 2003 | 196 | 0.090 |
Why?
|
| Escherichia coli Infections | 1 | 2013 | 184 | 0.090 |
Why?
|
| Incidence | 2 | 2015 | 3192 | 0.090 |
Why?
|
| Interferon-alpha | 1 | 2013 | 235 | 0.090 |
Why?
|
| Promoter Regions, Genetic | 4 | 2009 | 1211 | 0.090 |
Why?
|
| Binding, Competitive | 2 | 2009 | 153 | 0.090 |
Why?
|
| Dihydrotestosterone | 2 | 2009 | 72 | 0.090 |
Why?
|
| Urethra | 3 | 2003 | 84 | 0.090 |
Why?
|
| Cardiovascular Diseases | 2 | 2018 | 2002 | 0.090 |
Why?
|
| Follow-Up Studies | 9 | 2008 | 5090 | 0.090 |
Why?
|
| Water | 2 | 2006 | 189 | 0.090 |
Why?
|
| Drug Therapy, Combination | 3 | 2006 | 1145 | 0.090 |
Why?
|
| Gangliosides | 2 | 2003 | 66 | 0.090 |
Why?
|
| Reproducibility of Results | 1 | 2018 | 2863 | 0.090 |
Why?
|
| Stomach Neoplasms | 1 | 1997 | 564 | 0.090 |
Why?
|
| beta-Lactamases | 1 | 2013 | 210 | 0.090 |
Why?
|
| Risk Factors | 7 | 2020 | 10351 | 0.090 |
Why?
|
| Urogenital Neoplasms | 1 | 1991 | 14 | 0.090 |
Why?
|
| Meiosis | 2 | 2002 | 105 | 0.090 |
Why?
|
| Protein Binding | 2 | 2006 | 1673 | 0.090 |
Why?
|
| Brain | 2 | 2013 | 3018 | 0.080 |
Why?
|
| Receptors, Cell Surface | 2 | 2004 | 423 | 0.080 |
Why?
|
| Transplantation, Autologous | 3 | 2005 | 262 | 0.080 |
Why?
|
| Immunosuppressive Agents | 4 | 2003 | 641 | 0.080 |
Why?
|
| Urinary Diversion | 2 | 2008 | 39 | 0.080 |
Why?
|
| Tosyl Compounds | 2 | 2007 | 24 | 0.080 |
Why?
|
| Spleen | 2 | 2024 | 250 | 0.080 |
Why?
|
| Cohort Studies | 2 | 2018 | 4890 | 0.080 |
Why?
|
| Mutation | 4 | 2022 | 5920 | 0.080 |
Why?
|
| Predictive Value of Tests | 4 | 2008 | 2172 | 0.080 |
Why?
|
| Epidermis | 1 | 2010 | 62 | 0.080 |
Why?
|
| Anilides | 2 | 2007 | 52 | 0.080 |
Why?
|
| Trachea | 2 | 2003 | 204 | 0.080 |
Why?
|
| Vinblastine | 2 | 2018 | 55 | 0.080 |
Why?
|
| Hydronephrosis | 2 | 2007 | 36 | 0.080 |
Why?
|
| Genetic Therapy | 2 | 2013 | 679 | 0.080 |
Why?
|
| Open Reading Frames | 1 | 2010 | 204 | 0.080 |
Why?
|
| Amino Acid Sequence | 5 | 2004 | 2550 | 0.080 |
Why?
|
| RNA, Untranslated | 1 | 2010 | 109 | 0.080 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2018 | 746 | 0.080 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 3 | 2006 | 291 | 0.080 |
Why?
|
| Nitriles | 2 | 2007 | 141 | 0.080 |
Why?
|
| Bromisovalum | 1 | 1989 | 1 | 0.080 |
Why?
|
| Disease-Free Survival | 5 | 2006 | 903 | 0.080 |
Why?
|
| Hypogastric Plexus | 4 | 2003 | 7 | 0.080 |
Why?
|
| Recombinant Fusion Proteins | 2 | 2010 | 725 | 0.080 |
Why?
|
| Condylomata Acuminata | 1 | 1989 | 14 | 0.080 |
Why?
|
| Down-Regulation | 3 | 2006 | 651 | 0.080 |
Why?
|
| X Chromosome | 2 | 2001 | 332 | 0.080 |
Why?
|
| Hexosaminidases | 1 | 1989 | 6 | 0.080 |
Why?
|
| Cell Nucleus | 2 | 2010 | 558 | 0.080 |
Why?
|
| Inappropriate ADH Syndrome | 1 | 1989 | 7 | 0.080 |
Why?
|
| Endodermal Sinus Tumor | 1 | 2009 | 6 | 0.080 |
Why?
|
| ErbB Receptors | 1 | 1991 | 286 | 0.080 |
Why?
|
| gamma-Glutamyltransferase | 1 | 1989 | 49 | 0.080 |
Why?
|
| Cell Hypoxia | 2 | 2006 | 98 | 0.080 |
Why?
|
| Herpes Zoster | 1 | 1989 | 25 | 0.070 |
Why?
|
| Luciferases | 1 | 2009 | 126 | 0.070 |
Why?
|
| Bronchial Fistula | 2 | 2000 | 24 | 0.070 |
Why?
|
| Pleural Diseases | 2 | 2000 | 32 | 0.070 |
Why?
|
| Double-Blind Method | 3 | 2017 | 1589 | 0.070 |
Why?
|
| Nandrolone | 1 | 2008 | 6 | 0.070 |
Why?
|
| Prednisone | 3 | 2013 | 238 | 0.070 |
Why?
|
| Perforin | 2 | 1998 | 24 | 0.070 |
Why?
|
| Pore Forming Cytotoxic Proteins | 2 | 1998 | 19 | 0.070 |
Why?
|
| Granzymes | 2 | 1998 | 45 | 0.070 |
Why?
|
| Fas Ligand Protein | 2 | 1998 | 35 | 0.070 |
Why?
|
| Embryonic Development | 1 | 2010 | 212 | 0.070 |
Why?
|
| Protein Structure, Tertiary | 1 | 2010 | 722 | 0.070 |
Why?
|
| Testicular Hydrocele | 1 | 1988 | 2 | 0.070 |
Why?
|
| Mitomycins | 1 | 1988 | 8 | 0.070 |
Why?
|
| Hypopituitarism | 1 | 1988 | 18 | 0.070 |
Why?
|
| fas Receptor | 2 | 1998 | 43 | 0.070 |
Why?
|
| Hematopoiesis | 2 | 2022 | 200 | 0.070 |
Why?
|
| Pseudohypoparathyroidism | 1 | 1988 | 6 | 0.070 |
Why?
|
| Verapamil | 1 | 1988 | 46 | 0.070 |
Why?
|
| Transplantation, Heterotopic | 4 | 2003 | 24 | 0.070 |
Why?
|
| Puerperal Disorders | 1 | 1988 | 47 | 0.070 |
Why?
|
| Calcitonin | 1 | 1988 | 30 | 0.070 |
Why?
|
| Mitomycin | 3 | 2020 | 49 | 0.070 |
Why?
|
| Heterozygote | 2 | 2022 | 691 | 0.070 |
Why?
|
| Stroke | 1 | 2016 | 998 | 0.070 |
Why?
|
| Gonadotropin-Releasing Hormone | 1 | 1988 | 72 | 0.070 |
Why?
|
| Drug Screening Assays, Antitumor | 1 | 1988 | 105 | 0.070 |
Why?
|
| Quality of Life | 3 | 2014 | 2008 | 0.070 |
Why?
|
| Pancreatitis | 1 | 1989 | 137 | 0.070 |
Why?
|
| Parathyroid Hormone | 1 | 1988 | 77 | 0.070 |
Why?
|
| Herniorrhaphy | 2 | 2005 | 72 | 0.070 |
Why?
|
| Escherichia coli | 1 | 2013 | 968 | 0.070 |
Why?
|
| Cell Line | 2 | 2004 | 2565 | 0.070 |
Why?
|
| Patents as Topic | 1 | 2007 | 19 | 0.070 |
Why?
|
| Chemical and Drug Induced Liver Injury | 1 | 1989 | 134 | 0.070 |
Why?
|
| Polymorphism, Restriction Fragment Length | 3 | 1997 | 137 | 0.070 |
Why?
|
| Transurethral Resection of Prostate | 1 | 2007 | 8 | 0.070 |
Why?
|
| Allylestrenol | 1 | 2007 | 1 | 0.070 |
Why?
|
| Serine Endopeptidases | 2 | 1998 | 182 | 0.070 |
Why?
|
| Varicocele | 1 | 1988 | 61 | 0.070 |
Why?
|
| Cyproterone Acetate | 1 | 2007 | 11 | 0.070 |
Why?
|
| Rectum | 2 | 2006 | 99 | 0.070 |
Why?
|
| Imidazolidines | 1 | 2007 | 5 | 0.070 |
Why?
|
| Urine | 2 | 2013 | 88 | 0.070 |
Why?
|
| Methotrexate | 3 | 2007 | 312 | 0.070 |
Why?
|
| Transcriptional Activation | 1 | 2009 | 415 | 0.070 |
Why?
|
| Polymerase Chain Reaction | 4 | 2006 | 1489 | 0.070 |
Why?
|
| Hormones | 1 | 1988 | 167 | 0.070 |
Why?
|
| Ureteral Obstruction | 1 | 2008 | 102 | 0.070 |
Why?
|
| Neoplasm Grading | 2 | 2020 | 257 | 0.070 |
Why?
|
| Neoplasms | 2 | 2020 | 2833 | 0.070 |
Why?
|
| Logistic Models | 3 | 2025 | 1737 | 0.070 |
Why?
|
| RNA, Neoplasm | 1 | 2007 | 132 | 0.070 |
Why?
|
| Vascular Endothelial Growth Factor C | 1 | 2006 | 11 | 0.060 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-3 | 1 | 2006 | 8 | 0.060 |
Why?
|
| Anti-Infective Agents, Urinary | 2 | 2001 | 8 | 0.060 |
Why?
|
| Chaperonin 60 | 1 | 2006 | 31 | 0.060 |
Why?
|
| Mutagenesis, Site-Directed | 1 | 2007 | 299 | 0.060 |
Why?
|
| Urogenital System | 1 | 2006 | 35 | 0.060 |
Why?
|
| Retroperitoneal Fibrosis | 1 | 2006 | 2 | 0.060 |
Why?
|
| Recovery of Function | 2 | 2016 | 421 | 0.060 |
Why?
|
| Ganglioneuroma | 1 | 2006 | 17 | 0.060 |
Why?
|
| Drugs, Chinese Herbal | 1 | 2006 | 22 | 0.060 |
Why?
|
| Polymorphism, Single-Stranded Conformational | 2 | 1997 | 69 | 0.060 |
Why?
|
| Peripheral Nervous System Diseases | 2 | 1998 | 130 | 0.060 |
Why?
|
| Vena Cava Filters | 1 | 2006 | 19 | 0.060 |
Why?
|
| Plasmids | 1 | 2007 | 447 | 0.060 |
Why?
|
| Cross-Over Studies | 2 | 2017 | 323 | 0.060 |
Why?
|
| Exons | 2 | 2001 | 754 | 0.060 |
Why?
|
| Cause of Death | 1 | 2008 | 466 | 0.060 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2006 | 1597 | 0.060 |
Why?
|
| Receptors, Erythropoietin | 2 | 1998 | 13 | 0.060 |
Why?
|
| Vena Cava, Inferior | 1 | 2006 | 98 | 0.060 |
Why?
|
| Molecular Weight | 2 | 1997 | 298 | 0.060 |
Why?
|
| Bone Remodeling | 1 | 2006 | 55 | 0.060 |
Why?
|
| Chorionic Gonadotropin, beta Subunit, Human | 2 | 2004 | 25 | 0.060 |
Why?
|
| DNA, Neoplasm | 2 | 1997 | 287 | 0.060 |
Why?
|
| Culture Media, Conditioned | 2 | 2017 | 82 | 0.060 |
Why?
|
| Antibodies | 2 | 2004 | 351 | 0.060 |
Why?
|
| Muscle, Smooth | 2 | 2003 | 129 | 0.060 |
Why?
|
| Models, Genetic | 3 | 2009 | 744 | 0.060 |
Why?
|
| Reference Values | 4 | 2002 | 678 | 0.060 |
Why?
|
| Fibrin Tissue Adhesive | 1 | 2005 | 10 | 0.060 |
Why?
|
| Hernia | 1 | 2005 | 16 | 0.060 |
Why?
|
| Cell Separation | 1 | 2005 | 219 | 0.060 |
Why?
|
| IMP Dehydrogenase | 1 | 2025 | 27 | 0.060 |
Why?
|
| Blotting, Northern | 2 | 2004 | 236 | 0.060 |
Why?
|
| Microscopy, Electron | 3 | 2002 | 311 | 0.060 |
Why?
|
| Palpation | 1 | 2004 | 18 | 0.060 |
Why?
|
| Hyperaldosteronism | 1 | 2004 | 17 | 0.060 |
Why?
|
| Lymphoma, B-Cell | 1 | 2006 | 137 | 0.060 |
Why?
|
| Cushing Syndrome | 1 | 2004 | 22 | 0.060 |
Why?
|
| Cell Cycle | 2 | 2004 | 584 | 0.060 |
Why?
|
| Spinal Cord | 2 | 2003 | 243 | 0.050 |
Why?
|
| Castleman Disease | 1 | 2004 | 15 | 0.050 |
Why?
|
| Mediastinal Cyst | 1 | 2004 | 10 | 0.050 |
Why?
|
| Intestinal Diseases | 1 | 2005 | 68 | 0.050 |
Why?
|
| Pyrroles | 1 | 2006 | 176 | 0.050 |
Why?
|
| Imidazoles | 1 | 2006 | 212 | 0.050 |
Why?
|
| Hydroxylation | 1 | 2004 | 50 | 0.050 |
Why?
|
| Antigens, Differentiation | 2 | 2002 | 62 | 0.050 |
Why?
|
| Leiomyosarcoma | 1 | 2004 | 25 | 0.050 |
Why?
|
| Thoracic Surgery, Video-Assisted | 1 | 2004 | 55 | 0.050 |
Why?
|
| Dogs | 6 | 2003 | 602 | 0.050 |
Why?
|
| Pulmonary Embolism | 1 | 2006 | 159 | 0.050 |
Why?
|
| Procollagen-Proline Dioxygenase | 1 | 2004 | 32 | 0.050 |
Why?
|
| Palliative Care | 1 | 2008 | 437 | 0.050 |
Why?
|
| Decompression, Surgical | 1 | 2024 | 80 | 0.050 |
Why?
|
| Inhibin-beta Subunits | 1 | 2004 | 18 | 0.050 |
Why?
|
| Methylprednisolone | 1 | 2004 | 90 | 0.050 |
Why?
|
| Epithelium | 1 | 2005 | 339 | 0.050 |
Why?
|
| Antirheumatic Agents | 1 | 2006 | 118 | 0.050 |
Why?
|
| Pulmonary Edema | 1 | 2004 | 56 | 0.050 |
Why?
|
| Ligands | 3 | 2002 | 478 | 0.050 |
Why?
|
| Activins | 1 | 2004 | 72 | 0.050 |
Why?
|
| Erythroid Cells | 1 | 2024 | 23 | 0.050 |
Why?
|
| Thermodynamics | 1 | 2004 | 140 | 0.050 |
Why?
|
| Chest Pain | 1 | 2004 | 93 | 0.050 |
Why?
|
| Models, Molecular | 1 | 2007 | 1064 | 0.050 |
Why?
|
| Epigenesis, Genetic | 1 | 2009 | 712 | 0.050 |
Why?
|
| Administration, Intravesical | 2 | 2020 | 32 | 0.050 |
Why?
|
| Dyspnea | 1 | 2004 | 129 | 0.050 |
Why?
|
| Adrenocortical Carcinoma | 1 | 2003 | 11 | 0.050 |
Why?
|
| Oligosaccharides | 2 | 2003 | 73 | 0.050 |
Why?
|
| Urologic Surgical Procedures | 1 | 2003 | 61 | 0.050 |
Why?
|
| Adenoviridae | 5 | 2004 | 576 | 0.050 |
Why?
|
| Up-Regulation | 3 | 2004 | 829 | 0.050 |
Why?
|
| Age Factors | 4 | 2014 | 2763 | 0.050 |
Why?
|
| Ultrasonography | 2 | 2006 | 951 | 0.050 |
Why?
|
| Neoplasm Micrometastasis | 1 | 2023 | 13 | 0.050 |
Why?
|
| Intracranial Embolism and Thrombosis | 1 | 1983 | 5 | 0.050 |
Why?
|
| Neoplasms, Fibroepithelial | 1 | 2003 | 1 | 0.050 |
Why?
|
| Absorptiometry, Photon | 2 | 2001 | 195 | 0.050 |
Why?
|
| Tissue Engineering | 1 | 2005 | 166 | 0.050 |
Why?
|
| Hemangioma | 1 | 2004 | 93 | 0.050 |
Why?
|
| Abatacept | 4 | 2004 | 23 | 0.050 |
Why?
|
| Ileum | 1 | 2003 | 123 | 0.050 |
Why?
|
| Urea | 2 | 1997 | 223 | 0.050 |
Why?
|
| Prospective Studies | 2 | 2023 | 6168 | 0.050 |
Why?
|
| Radiography | 2 | 2000 | 748 | 0.050 |
Why?
|
| Follicle Stimulating Hormone | 2 | 1997 | 185 | 0.050 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2007 | 770 | 0.050 |
Why?
|
| Calcinosis | 1 | 2004 | 183 | 0.050 |
Why?
|
| Drainage | 1 | 2004 | 251 | 0.050 |
Why?
|
| Adrenal Cortex Neoplasms | 1 | 1983 | 24 | 0.050 |
Why?
|
| Floxuridine | 1 | 2002 | 8 | 0.050 |
Why?
|
| Thymidine Phosphorylase | 1 | 2002 | 13 | 0.050 |
Why?
|
| Proto-Oncogene Proteins c-myc | 1 | 2004 | 191 | 0.050 |
Why?
|
| Kinetics | 2 | 2020 | 1092 | 0.050 |
Why?
|
| Cloning, Molecular | 4 | 1998 | 786 | 0.050 |
Why?
|
| Epithelial Cells | 2 | 2005 | 871 | 0.050 |
Why?
|
| Carcinoma, Signet Ring Cell | 1 | 2002 | 11 | 0.050 |
Why?
|
| Neoplasms, Unknown Primary | 1 | 2002 | 13 | 0.050 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2016 | 1025 | 0.050 |
Why?
|
| Polyps | 1 | 2003 | 39 | 0.050 |
Why?
|
| Eukaryotic Cells | 1 | 2002 | 29 | 0.050 |
Why?
|
| Cranial Irradiation | 1 | 2022 | 71 | 0.050 |
Why?
|
| Genetic Vectors | 5 | 2004 | 891 | 0.050 |
Why?
|
| DNA Methylation | 1 | 2009 | 1035 | 0.050 |
Why?
|
| Hypoxia | 1 | 2004 | 247 | 0.050 |
Why?
|
| Urinary Tract Infections | 2 | 2001 | 309 | 0.050 |
Why?
|
| In Situ Nick-End Labeling | 2 | 2000 | 121 | 0.050 |
Why?
|
| Bombesin | 1 | 2002 | 4 | 0.050 |
Why?
|
| Fluorouracil | 1 | 2002 | 135 | 0.050 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 1 | 2023 | 145 | 0.050 |
Why?
|
| Glucuronosyltransferase | 1 | 2022 | 62 | 0.050 |
Why?
|
| Odds Ratio | 1 | 2025 | 1186 | 0.050 |
Why?
|
| Adrenergic alpha-Antagonists | 1 | 2002 | 40 | 0.050 |
Why?
|
| Naphthalenes | 1 | 2002 | 36 | 0.050 |
Why?
|
| Analysis of Variance | 4 | 2008 | 950 | 0.050 |
Why?
|
| Urachus | 1 | 2001 | 3 | 0.050 |
Why?
|
| Heart Ventricles | 1 | 2006 | 748 | 0.050 |
Why?
|
| Mice, Inbred DBA | 2 | 1998 | 54 | 0.050 |
Why?
|
| Sertoli Cells | 1 | 2002 | 76 | 0.050 |
Why?
|
| Ofloxacin | 1 | 2001 | 31 | 0.050 |
Why?
|
| Hyperplasia | 1 | 2002 | 188 | 0.040 |
Why?
|
| Levofloxacin | 1 | 2001 | 48 | 0.040 |
Why?
|
| Injections | 1 | 2002 | 134 | 0.040 |
Why?
|
| Rats, Sprague-Dawley | 2 | 2001 | 1132 | 0.040 |
Why?
|
| Tretinoin | 1 | 2022 | 93 | 0.040 |
Why?
|
| Induction Chemotherapy | 1 | 2022 | 54 | 0.040 |
Why?
|
| Acute Disease | 2 | 1998 | 1039 | 0.040 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2025 | 572 | 0.040 |
Why?
|
| Spermatocytes | 1 | 2001 | 22 | 0.040 |
Why?
|
| Spermatids | 1 | 2001 | 26 | 0.040 |
Why?
|
| Surgical Wound Infection | 1 | 2003 | 266 | 0.040 |
Why?
|
| Interleukin-2 | 1 | 2022 | 232 | 0.040 |
Why?
|
| Sex Factors | 1 | 2025 | 1292 | 0.040 |
Why?
|
| Prostatic Hyperplasia | 1 | 2002 | 114 | 0.040 |
Why?
|
| Endothelial Growth Factors | 1 | 2001 | 51 | 0.040 |
Why?
|
| Chromosome Mapping | 2 | 2001 | 1070 | 0.040 |
Why?
|
| Multicenter Studies as Topic | 2 | 2020 | 280 | 0.040 |
Why?
|
| Macromolecular Substances | 1 | 2001 | 141 | 0.040 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2002 | 170 | 0.040 |
Why?
|
| Genitalia, Male | 1 | 2001 | 34 | 0.040 |
Why?
|
| Fushi Tarazu Transcription Factors | 2 | 1997 | 7 | 0.040 |
Why?
|
| Thyrotropin | 1 | 2000 | 53 | 0.040 |
Why?
|
| Iron | 1 | 2024 | 295 | 0.040 |
Why?
|
| Tokyo | 1 | 2020 | 2 | 0.040 |
Why?
|
| Cystoscopes | 1 | 2020 | 1 | 0.040 |
Why?
|
| Models, Biological | 1 | 2006 | 1374 | 0.040 |
Why?
|
| Infertility, Male | 1 | 2004 | 285 | 0.040 |
Why?
|
| Melanoma | 1 | 2008 | 927 | 0.040 |
Why?
|
| RNA Helicases | 1 | 2001 | 68 | 0.040 |
Why?
|
| Osmolar Concentration | 1 | 2000 | 151 | 0.040 |
Why?
|
| Triiodothyronine | 1 | 2000 | 54 | 0.040 |
Why?
|
| Arthroplasty, Replacement | 1 | 2001 | 25 | 0.040 |
Why?
|
| Steroidogenic Factor 1 | 2 | 1997 | 35 | 0.040 |
Why?
|
| Adrenal Insufficiency | 1 | 2000 | 29 | 0.040 |
Why?
|
| Blood | 1 | 2000 | 100 | 0.040 |
Why?
|
| Disease Progression | 3 | 2002 | 2104 | 0.040 |
Why?
|
| Thyroxine | 1 | 2000 | 62 | 0.040 |
Why?
|
| Nerve Regeneration | 1 | 2001 | 71 | 0.040 |
Why?
|
| Respiratory Tract Fistula | 1 | 2000 | 17 | 0.040 |
Why?
|
| Piperazines | 1 | 2002 | 245 | 0.040 |
Why?
|
| Acetylcysteine | 1 | 2001 | 79 | 0.040 |
Why?
|
| Antigens, Tumor-Associated, Carbohydrate | 1 | 2000 | 12 | 0.040 |
Why?
|
| Lewis X Antigen | 1 | 2000 | 11 | 0.040 |
Why?
|
| Aquaporin 1 | 2 | 1997 | 6 | 0.040 |
Why?
|
| Mice, Inbred Strains | 2 | 1998 | 290 | 0.040 |
Why?
|
| Stromal Cells | 2 | 2017 | 296 | 0.040 |
Why?
|
| Transgenes | 1 | 2001 | 330 | 0.040 |
Why?
|
| Sulfonamides | 1 | 2002 | 270 | 0.040 |
Why?
|
| Macrophages | 1 | 2004 | 644 | 0.040 |
Why?
|
| Antibodies, Monoclonal | 1 | 2006 | 990 | 0.040 |
Why?
|
| Tumor Burden | 1 | 2020 | 228 | 0.040 |
Why?
|
| Hypoxia-Inducible Factor 1 | 2 | 2013 | 18 | 0.040 |
Why?
|
| Intermediate Filament Proteins | 1 | 1999 | 23 | 0.040 |
Why?
|
| Cell Division | 4 | 2004 | 721 | 0.040 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2022 | 639 | 0.040 |
Why?
|
| Vagina | 1 | 2001 | 201 | 0.040 |
Why?
|
| Ovary | 2 | 2000 | 356 | 0.040 |
Why?
|
| Antidepressive Agents | 1 | 2022 | 313 | 0.040 |
Why?
|
| Vincristine | 2 | 2013 | 193 | 0.040 |
Why?
|
| Saccharomyces cerevisiae Proteins | 1 | 2001 | 265 | 0.040 |
Why?
|
| Tissue Transplantation | 1 | 1999 | 11 | 0.040 |
Why?
|
| Polymorphism, Genetic | 1 | 2022 | 788 | 0.040 |
Why?
|
| Chemokine CCL2 | 1 | 2019 | 110 | 0.040 |
Why?
|
| Synaptic Transmission | 1 | 2001 | 318 | 0.040 |
Why?
|
| Didanosine | 1 | 1998 | 5 | 0.040 |
Why?
|
| Saquinavir | 1 | 1998 | 5 | 0.040 |
Why?
|
| Cell Adhesion Molecules | 1 | 2000 | 216 | 0.040 |
Why?
|
| DNA Fragmentation | 1 | 1998 | 54 | 0.040 |
Why?
|
| Zidovudine | 1 | 1998 | 23 | 0.040 |
Why?
|
| Tissue and Organ Harvesting | 1 | 1999 | 39 | 0.040 |
Why?
|
| Methods | 1 | 1998 | 123 | 0.040 |
Why?
|
| Lymph Node Excision | 3 | 2006 | 167 | 0.040 |
Why?
|
| Gene Deletion | 2 | 1999 | 767 | 0.040 |
Why?
|
| Microphthalmos | 1 | 1999 | 55 | 0.040 |
Why?
|
| Transplantation, Isogeneic | 1 | 1998 | 15 | 0.040 |
Why?
|
| Kidney Medulla | 1 | 2018 | 19 | 0.040 |
Why?
|
| Sex Characteristics | 1 | 2000 | 305 | 0.040 |
Why?
|
| Disorders of Sex Development | 1 | 1999 | 70 | 0.040 |
Why?
|
| Crosses, Genetic | 1 | 1998 | 159 | 0.040 |
Why?
|
| Spleen Focus-Forming Viruses | 1 | 1998 | 1 | 0.040 |
Why?
|
| Ambulatory Care | 1 | 2001 | 388 | 0.040 |
Why?
|
| Factor VIII | 1 | 1998 | 47 | 0.040 |
Why?
|
| Erythroid Precursor Cells | 1 | 1998 | 20 | 0.040 |
Why?
|
| Biopsy | 3 | 2008 | 1219 | 0.040 |
Why?
|
| Receptors, Glucocorticoid | 3 | 2006 | 105 | 0.040 |
Why?
|
| CD4 Lymphocyte Count | 1 | 1998 | 228 | 0.040 |
Why?
|
| Hypogonadism | 1 | 2002 | 319 | 0.030 |
Why?
|
| Primary Cell Culture | 1 | 2018 | 103 | 0.030 |
Why?
|
| Antigens, Surface | 1 | 1998 | 114 | 0.030 |
Why?
|
| Dacarbazine | 1 | 2018 | 91 | 0.030 |
Why?
|
| Blood Pressure | 2 | 1994 | 1302 | 0.030 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2002 | 721 | 0.030 |
Why?
|
| Administration, Oral | 2 | 2001 | 677 | 0.030 |
Why?
|
| Sacrococcygeal Region | 1 | 1998 | 37 | 0.030 |
Why?
|
| Molecular Targeted Therapy | 1 | 2020 | 380 | 0.030 |
Why?
|
| Cyclophosphamide | 2 | 2013 | 417 | 0.030 |
Why?
|
| Rats, Wistar | 2 | 1997 | 306 | 0.030 |
Why?
|
| Pleura | 1 | 1997 | 27 | 0.030 |
Why?
|
| Milk Proteins | 1 | 1998 | 83 | 0.030 |
Why?
|
| Receptors, LHRH | 1 | 1997 | 13 | 0.030 |
Why?
|
| T-Lymphocytes, Cytotoxic | 2 | 1998 | 512 | 0.030 |
Why?
|
| Denervation | 3 | 2003 | 27 | 0.030 |
Why?
|
| Diethylstilbestrol | 1 | 1997 | 41 | 0.030 |
Why?
|
| Hypospadias | 1 | 1999 | 81 | 0.030 |
Why?
|
| Porins | 1 | 1997 | 38 | 0.030 |
Why?
|
| Fibrosis | 1 | 2019 | 393 | 0.030 |
Why?
|
| Diptera | 1 | 1997 | 26 | 0.030 |
Why?
|
| Cell Death | 1 | 1998 | 234 | 0.030 |
Why?
|
| Leuprolide | 1 | 1997 | 23 | 0.030 |
Why?
|
| Paraneoplastic Syndromes | 1 | 1997 | 14 | 0.030 |
Why?
|
| Fistula | 1 | 1997 | 50 | 0.030 |
Why?
|
| Gene Library | 2 | 1997 | 212 | 0.030 |
Why?
|
| Chondrosarcoma | 1 | 1997 | 13 | 0.030 |
Why?
|
| Homeodomain Proteins | 2 | 1997 | 539 | 0.030 |
Why?
|
| Glycerol | 1 | 1997 | 80 | 0.030 |
Why?
|
| Carcinoma, Small Cell | 1 | 1997 | 39 | 0.030 |
Why?
|
| Erythropoietin | 1 | 1998 | 105 | 0.030 |
Why?
|
| Viral Envelope Proteins | 1 | 1998 | 152 | 0.030 |
Why?
|
| Seminiferous Tubules | 3 | 2002 | 15 | 0.030 |
Why?
|
| Postoperative Period | 3 | 2003 | 324 | 0.030 |
Why?
|
| Metamorphosis, Biological | 1 | 1996 | 7 | 0.030 |
Why?
|
| Vulva | 1 | 1996 | 14 | 0.030 |
Why?
|
| Coculture Techniques | 1 | 2017 | 229 | 0.030 |
Why?
|
| Endothelium, Vascular | 1 | 2000 | 463 | 0.030 |
Why?
|
| Ribs | 1 | 1997 | 53 | 0.030 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 1998 | 220 | 0.030 |
Why?
|
| Codon | 1 | 1997 | 96 | 0.030 |
Why?
|
| Disease Susceptibility | 1 | 1998 | 276 | 0.030 |
Why?
|
| Joint Instability | 1 | 1997 | 57 | 0.030 |
Why?
|
| Matrix Metalloproteinase 2 | 1 | 1997 | 88 | 0.030 |
Why?
|
| Aquaporin 6 | 1 | 1996 | 2 | 0.030 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2001 | 1178 | 0.030 |
Why?
|
| Aquaporin 2 | 1 | 1996 | 6 | 0.030 |
Why?
|
| Immunophenotyping | 1 | 2017 | 330 | 0.030 |
Why?
|
| DNA Transposable Elements | 1 | 1997 | 180 | 0.030 |
Why?
|
| Drosophila | 1 | 2001 | 781 | 0.030 |
Why?
|
| Homozygote | 1 | 1998 | 541 | 0.030 |
Why?
|
| Risk Assessment | 2 | 2020 | 3417 | 0.030 |
Why?
|
| Antigens, CD19 | 1 | 2017 | 170 | 0.030 |
Why?
|
| Animals, Genetically Modified | 1 | 1997 | 325 | 0.030 |
Why?
|
| Carrier Proteins | 1 | 2001 | 1011 | 0.030 |
Why?
|
| Cross-Sectional Studies | 1 | 2025 | 3652 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 21 | 1 | 2016 | 26 | 0.030 |
Why?
|
| Hand Strength | 1 | 2016 | 56 | 0.030 |
Why?
|
| Positron Emission Tomography Computed Tomography | 1 | 2016 | 74 | 0.030 |
Why?
|
| Tumor Suppressor Proteins | 3 | 2003 | 473 | 0.030 |
Why?
|
| Radionuclide Imaging | 1 | 1996 | 122 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 8 | 1 | 2016 | 78 | 0.030 |
Why?
|
| Knee Joint | 1 | 1997 | 162 | 0.030 |
Why?
|
| Blood Group Antigens | 1 | 1996 | 57 | 0.030 |
Why?
|
| Transplantation, Heterologous | 2 | 2006 | 248 | 0.030 |
Why?
|
| Penile Erection | 1 | 1996 | 80 | 0.030 |
Why?
|
| Transcriptome | 1 | 2022 | 1064 | 0.030 |
Why?
|
| Heart Failure | 1 | 1988 | 2161 | 0.030 |
Why?
|
| Uroplakin III | 2 | 2006 | 2 | 0.030 |
Why?
|
| Immunoglobulin G | 1 | 1998 | 763 | 0.030 |
Why?
|
| Analgesia, Epidural | 1 | 1995 | 29 | 0.030 |
Why?
|
| Pain Measurement | 1 | 2017 | 345 | 0.030 |
Why?
|
| Drug Synergism | 2 | 2002 | 231 | 0.030 |
Why?
|
| Child | 7 | 2011 | 25059 | 0.030 |
Why?
|
| Disability Evaluation | 1 | 2016 | 186 | 0.030 |
Why?
|
| 11-beta-Hydroxysteroid Dehydrogenases | 1 | 1994 | 4 | 0.030 |
Why?
|
| Mineralocorticoids | 1 | 1994 | 4 | 0.030 |
Why?
|
| Glycyrrhizic Acid | 1 | 1994 | 3 | 0.030 |
Why?
|
| Desoxycorticosterone | 1 | 1994 | 12 | 0.030 |
Why?
|
| Hydroxysteroid Dehydrogenases | 1 | 1994 | 18 | 0.030 |
Why?
|
| Spironolactone | 1 | 1994 | 22 | 0.030 |
Why?
|
| Corticosterone | 1 | 1994 | 55 | 0.030 |
Why?
|
| Pain Management | 1 | 2017 | 195 | 0.030 |
Why?
|
| Aldosterone | 1 | 1994 | 57 | 0.030 |
Why?
|
| Renin | 1 | 1994 | 78 | 0.030 |
Why?
|
| Infusions, Intravenous | 1 | 2016 | 523 | 0.030 |
Why?
|
| Fat Body | 1 | 1994 | 2 | 0.030 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2000 | 746 | 0.030 |
Why?
|
| Binding Sites | 2 | 2013 | 1193 | 0.030 |
Why?
|
| Sequence Analysis | 1 | 1994 | 51 | 0.030 |
Why?
|
| Protein Sorting Signals | 1 | 1994 | 39 | 0.030 |
Why?
|
| DNA, Ribosomal | 1 | 1994 | 53 | 0.030 |
Why?
|
| Genes, Plant | 1 | 1994 | 38 | 0.030 |
Why?
|
| Buprenorphine | 1 | 1995 | 106 | 0.030 |
Why?
|
| Oryza | 1 | 1994 | 29 | 0.030 |
Why?
|
| Radiography, Abdominal | 2 | 2004 | 45 | 0.030 |
Why?
|
| Aging | 1 | 2001 | 1193 | 0.030 |
Why?
|
| Protein Biosynthesis | 1 | 1996 | 564 | 0.030 |
Why?
|
| Bone and Bones | 1 | 1996 | 294 | 0.030 |
Why?
|
| Potassium | 1 | 1994 | 259 | 0.030 |
Why?
|
| Myocardium | 1 | 1998 | 835 | 0.030 |
Why?
|
| Von Hippel-Lindau Tumor Suppressor Protein | 1 | 2013 | 37 | 0.030 |
Why?
|
| Extravasation of Diagnostic and Therapeutic Materials | 1 | 1993 | 6 | 0.030 |
Why?
|
| Myocytes, Cardiac | 1 | 2018 | 609 | 0.020 |
Why?
|
| Cerebellar Diseases | 1 | 1994 | 77 | 0.020 |
Why?
|
| Fractures, Bone | 1 | 1995 | 186 | 0.020 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 1 | 2013 | 59 | 0.020 |
Why?
|
| Receptors, Interleukin-2 | 1 | 1992 | 40 | 0.020 |
Why?
|
| Mutagenesis | 1 | 1994 | 333 | 0.020 |
Why?
|
| Sphingosine | 2 | 2003 | 15 | 0.020 |
Why?
|
| Fingolimod Hydrochloride | 2 | 2003 | 33 | 0.020 |
Why?
|
| Joint Prosthesis | 1 | 1992 | 17 | 0.020 |
Why?
|
| Receptor, Notch1 | 2 | 2004 | 73 | 0.020 |
Why?
|
| DNA Primers | 2 | 2004 | 602 | 0.020 |
Why?
|
| Cerebral Hemorrhage | 1 | 1994 | 147 | 0.020 |
Why?
|
| Splanchnic Nerves | 2 | 2003 | 2 | 0.020 |
Why?
|
| Pain, Postoperative | 1 | 1995 | 260 | 0.020 |
Why?
|
| Mice, Inbred BALB C | 2 | 2006 | 1001 | 0.020 |
Why?
|
| Morphogenesis | 2 | 2004 | 190 | 0.020 |
Why?
|
| CA-19-9 Antigen | 2 | 2003 | 10 | 0.020 |
Why?
|
| beta Catenin | 2 | 2003 | 203 | 0.020 |
Why?
|
| Cell Adhesion | 2 | 2005 | 298 | 0.020 |
Why?
|
| Rituximab | 1 | 2013 | 165 | 0.020 |
Why?
|
| Amyloidosis | 1 | 1992 | 74 | 0.020 |
Why?
|
| Electric Stimulation | 2 | 2003 | 238 | 0.020 |
Why?
|
| Blotting, Western | 2 | 2004 | 1019 | 0.020 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 2 | 2004 | 280 | 0.020 |
Why?
|
| Child, Preschool | 3 | 2009 | 14341 | 0.020 |
Why?
|
| Models, Animal | 2 | 2003 | 455 | 0.020 |
Why?
|
| beta 2-Microglobulin | 1 | 1990 | 36 | 0.020 |
Why?
|
| Mifepristone | 2 | 2004 | 88 | 0.020 |
Why?
|
| Cell Survival | 1 | 2013 | 833 | 0.020 |
Why?
|
| Penile Neoplasms | 1 | 1991 | 37 | 0.020 |
Why?
|
| Analgesics, Opioid | 1 | 1995 | 449 | 0.020 |
Why?
|
| Keratins | 1 | 1990 | 51 | 0.020 |
Why?
|
| Surgeons | 1 | 2015 | 276 | 0.020 |
Why?
|
| Mice, Knockout | 1 | 1998 | 3705 | 0.020 |
Why?
|
| Neural Pathways | 2 | 2003 | 260 | 0.020 |
Why?
|
| Kidney Function Tests | 1 | 1990 | 121 | 0.020 |
Why?
|
| Hematuria | 1 | 1990 | 49 | 0.020 |
Why?
|
| Rabbits | 2 | 2002 | 640 | 0.020 |
Why?
|
| Time and Motion Studies | 1 | 2010 | 16 | 0.020 |
Why?
|
| Endoscopes | 1 | 2010 | 18 | 0.020 |
Why?
|
| Carotenoids | 1 | 1991 | 76 | 0.020 |
Why?
|
| Surgical Instruments | 1 | 2010 | 54 | 0.020 |
Why?
|
| Bleomycin | 1 | 2010 | 110 | 0.020 |
Why?
|
| Urodynamics | 1 | 1989 | 36 | 0.020 |
Why?
|
| Phimosis | 1 | 1989 | 1 | 0.020 |
Why?
|
| Urethritis | 1 | 1989 | 2 | 0.020 |
Why?
|
| Lipoma | 1 | 1989 | 24 | 0.020 |
Why?
|
| Mammary Neoplasms, Experimental | 1 | 1991 | 236 | 0.020 |
Why?
|
| Skin Ulcer | 1 | 1989 | 31 | 0.020 |
Why?
|
| Epoprostenol | 1 | 1989 | 42 | 0.020 |
Why?
|
| Prostatitis | 1 | 1989 | 20 | 0.020 |
Why?
|
| Aztreonam | 1 | 1988 | 5 | 0.020 |
Why?
|
| Herpesvirus 3, Human | 1 | 1989 | 29 | 0.020 |
Why?
|
| Creatinine | 1 | 1990 | 359 | 0.020 |
Why?
|
| Formazans | 1 | 2008 | 1 | 0.020 |
Why?
|
| Tetrazolium Salts | 1 | 2008 | 11 | 0.020 |
Why?
|
| Fluorescence Polarization | 1 | 2008 | 10 | 0.020 |
Why?
|
| Translocation, Genetic | 1 | 2011 | 348 | 0.020 |
Why?
|
| Cell Growth Processes | 1 | 2008 | 60 | 0.020 |
Why?
|
| Nomograms | 1 | 2008 | 35 | 0.020 |
Why?
|
| Salvage Therapy | 1 | 2010 | 175 | 0.020 |
Why?
|
| Pentagastrin | 1 | 1988 | 6 | 0.020 |
Why?
|
| Drug Interactions | 2 | 2004 | 238 | 0.020 |
Why?
|
| Cell Communication | 1 | 1989 | 181 | 0.020 |
Why?
|
| Lymphatic System | 1 | 1988 | 19 | 0.020 |
Why?
|
| Sequence Analysis, DNA | 1 | 1994 | 1738 | 0.020 |
Why?
|
| Fluorescent Antibody Technique | 2 | 2004 | 413 | 0.020 |
Why?
|
| Genomic Imprinting | 1 | 2009 | 126 | 0.020 |
Why?
|
| Cell Proliferation | 2 | 2006 | 2393 | 0.020 |
Why?
|
| Ligation | 1 | 1988 | 136 | 0.020 |
Why?
|
| Hypothermia | 1 | 1988 | 60 | 0.020 |
Why?
|
| Luteinizing Hormone | 1 | 1988 | 133 | 0.020 |
Why?
|
| Chorionic Gonadotropin | 1 | 1988 | 79 | 0.020 |
Why?
|
| Veins | 1 | 1988 | 99 | 0.020 |
Why?
|
| Pain | 1 | 1990 | 429 | 0.020 |
Why?
|
| Drug Design | 1 | 2008 | 154 | 0.020 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 1988 | 61 | 0.020 |
Why?
|
| Acute Kidney Injury | 1 | 1994 | 601 | 0.020 |
Why?
|
| Muscles | 1 | 2007 | 224 | 0.020 |
Why?
|
| Platelet Aggregation Inhibitors | 1 | 1989 | 260 | 0.020 |
Why?
|
| Postpartum Hemorrhage | 1 | 1988 | 110 | 0.020 |
Why?
|
| In Vitro Techniques | 1 | 1988 | 821 | 0.020 |
Why?
|
| Paclitaxel | 1 | 2007 | 130 | 0.020 |
Why?
|
| Sequence Alignment | 2 | 1998 | 584 | 0.020 |
Why?
|
| Mesna | 1 | 2006 | 7 | 0.020 |
Why?
|
| Digital Rectal Examination | 1 | 2006 | 6 | 0.020 |
Why?
|
| Mitoxantrone | 1 | 2006 | 27 | 0.020 |
Why?
|
| Organ Size | 2 | 2002 | 437 | 0.020 |
Why?
|
| Neoplasm Seeding | 1 | 2006 | 12 | 0.020 |
Why?
|
| Therapeutic Irrigation | 1 | 2006 | 43 | 0.020 |
Why?
|
| Equipment Failure | 1 | 2006 | 128 | 0.020 |
Why?
|
| Mice, Nude | 2 | 2002 | 705 | 0.020 |
Why?
|
| Alkaline Phosphatase | 1 | 2006 | 92 | 0.020 |
Why?
|
| Tissue Adhesions | 1 | 2005 | 29 | 0.020 |
Why?
|
| Survivors | 1 | 2008 | 344 | 0.010 |
Why?
|
| Bone Resorption | 1 | 2006 | 50 | 0.010 |
Why?
|
| Heat-Shock Proteins | 1 | 2006 | 175 | 0.010 |
Why?
|
| Infliximab | 1 | 2006 | 65 | 0.010 |
Why?
|
| Models, Statistical | 1 | 2008 | 465 | 0.010 |
Why?
|
| Systemic Inflammatory Response Syndrome | 1 | 2007 | 189 | 0.010 |
Why?
|
| Syndrome | 1 | 1988 | 1113 | 0.010 |
Why?
|
| Collagen Type I | 1 | 2006 | 114 | 0.010 |
Why?
|
| Blotting, Southern | 2 | 1996 | 207 | 0.010 |
Why?
|
| Adrenal Cortex Hormones | 2 | 2001 | 332 | 0.010 |
Why?
|
| Interleukin-8 | 1 | 2006 | 203 | 0.010 |
Why?
|
| Tissue Adhesives | 1 | 2005 | 34 | 0.010 |
Why?
|
| Ejaculation | 1 | 2004 | 21 | 0.010 |
Why?
|
| Preoperative Care | 1 | 2007 | 355 | 0.010 |
Why?
|
| Immunoenzyme Techniques | 1 | 2004 | 243 | 0.010 |
Why?
|
| Serrate-Jagged Proteins | 1 | 2004 | 36 | 0.010 |
Why?
|
| Mediastinum | 1 | 2004 | 47 | 0.010 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2004 | 82 | 0.010 |
Why?
|
| Jagged-1 Protein | 1 | 2004 | 51 | 0.010 |
Why?
|
| Length of Stay | 1 | 2010 | 1313 | 0.010 |
Why?
|
| Hypoalbuminemia | 1 | 2003 | 15 | 0.010 |
Why?
|
| COS Cells | 1 | 2004 | 248 | 0.010 |
Why?
|
| BRCA1 Protein | 1 | 2004 | 77 | 0.010 |
Why?
|
| Tuberculosis, Urogenital | 1 | 2003 | 1 | 0.010 |
Why?
|
| Surgical Flaps | 1 | 2005 | 190 | 0.010 |
Why?
|
| Immunoprecipitation | 1 | 2004 | 185 | 0.010 |
Why?
|
| Chromatin Immunoprecipitation | 1 | 2004 | 230 | 0.010 |
Why?
|
| Equipment Contamination | 1 | 2003 | 40 | 0.010 |
Why?
|
| Urinary Bladder Diseases | 1 | 2003 | 33 | 0.010 |
Why?
|
| Disease Models, Animal | 2 | 2005 | 4423 | 0.010 |
Why?
|
| Ganglia, Sympathetic | 1 | 2003 | 8 | 0.010 |
Why?
|
| Lumbosacral Region | 1 | 2003 | 22 | 0.010 |
Why?
|
| Amino Acids | 1 | 2006 | 612 | 0.010 |
Why?
|
| Cyclohexanes | 1 | 2002 | 8 | 0.010 |
Why?
|
| Aspirin | 1 | 2004 | 200 | 0.010 |
Why?
|
| Anastomosis, Surgical | 1 | 2003 | 159 | 0.010 |
Why?
|
| Pressure | 1 | 2003 | 123 | 0.010 |
Why?
|
| Colony-Forming Units Assay | 1 | 2002 | 60 | 0.010 |
Why?
|
| Nicardipine | 1 | 2002 | 13 | 0.010 |
Why?
|
| Antibodies, Viral | 1 | 1989 | 1132 | 0.010 |
Why?
|
| Fibrinolytic Agents | 1 | 2004 | 195 | 0.010 |
Why?
|
| Calcium-Binding Proteins | 1 | 2004 | 324 | 0.010 |
Why?
|
| Sesquiterpenes | 1 | 2002 | 26 | 0.010 |
Why?
|
| Microscopy, Confocal | 1 | 2004 | 362 | 0.010 |
Why?
|
| Enzyme Induction | 1 | 2002 | 98 | 0.010 |
Why?
|
| Kallmann Syndrome | 1 | 2002 | 13 | 0.010 |
Why?
|
| Cellular Senescence | 1 | 2004 | 180 | 0.010 |
Why?
|
| RNA Interference | 1 | 2004 | 495 | 0.010 |
Why?
|
| Mutagens | 1 | 2002 | 48 | 0.010 |
Why?
|
| Lymph Nodes | 1 | 2004 | 373 | 0.010 |
Why?
|
| Receptors, Notch | 1 | 2004 | 195 | 0.010 |
Why?
|
| Cryptorchidism | 1 | 2002 | 38 | 0.010 |
Why?
|
| Multienzyme Complexes | 1 | 2002 | 78 | 0.010 |
Why?
|
| Jagged-2 Protein | 1 | 2001 | 5 | 0.010 |
Why?
|
| Injections, Intramuscular | 1 | 2002 | 181 | 0.010 |
Why?
|
| Proto-Oncogene Proteins c-mdm2 | 1 | 2002 | 79 | 0.010 |
Why?
|
| Cysteine Endopeptidases | 1 | 2002 | 105 | 0.010 |
Why?
|
| Phosphopyruvate Hydratase | 1 | 2002 | 28 | 0.010 |
Why?
|
| Thoracic Surgical Procedures | 1 | 2003 | 100 | 0.010 |
Why?
|
| Urinary Tract | 1 | 2002 | 61 | 0.010 |
Why?
|
| Radiotherapy, Conformal | 1 | 2001 | 45 | 0.010 |
Why?
|
| Cell Count | 1 | 2002 | 218 | 0.010 |
Why?
|
| Ultraviolet Rays | 1 | 2002 | 192 | 0.010 |
Why?
|
| Phosphoprotein Phosphatases | 1 | 2002 | 114 | 0.010 |
Why?
|
| Wound Healing | 1 | 2005 | 445 | 0.010 |
Why?
|
| Efferent Pathways | 1 | 2001 | 7 | 0.010 |
Why?
|
| Mesentery | 1 | 2001 | 27 | 0.010 |
Why?
|
| Vascular Endothelial Growth Factors | 1 | 2001 | 51 | 0.010 |
Why?
|
| Proteasome Endopeptidase Complex | 1 | 2002 | 232 | 0.010 |
Why?
|
| Matrix Metalloproteinase Inhibitors | 1 | 2001 | 16 | 0.010 |
Why?
|
| Tetradecanoylphorbol Acetate | 1 | 2001 | 59 | 0.010 |
Why?
|
| Vas Deferens | 1 | 2001 | 22 | 0.010 |
Why?
|
| Ureter | 1 | 2002 | 95 | 0.010 |
Why?
|
| Basement Membrane | 1 | 2001 | 45 | 0.010 |
Why?
|
| Indomethacin | 2 | 1992 | 81 | 0.010 |
Why?
|
| Muscle Contraction | 1 | 2001 | 149 | 0.010 |
Why?
|
| CTLA-4 Antigen | 1 | 2000 | 63 | 0.010 |
Why?
|
| Epididymis | 1 | 2001 | 60 | 0.010 |
Why?
|
| Doxycycline | 1 | 2001 | 119 | 0.010 |
Why?
|
| Vindesine | 1 | 2000 | 1 | 0.010 |
Why?
|
| Probability | 1 | 2001 | 300 | 0.010 |
Why?
|
| Functional Laterality | 1 | 2001 | 173 | 0.010 |
Why?
|
| Stress, Physiological | 1 | 2002 | 256 | 0.010 |
Why?
|
| Leg | 1 | 2001 | 124 | 0.010 |
Why?
|
| DNA | 2 | 1998 | 1430 | 0.010 |
Why?
|
| Cell Cycle Proteins | 1 | 2004 | 658 | 0.010 |
Why?
|
| Statistics, Nonparametric | 1 | 2001 | 418 | 0.010 |
Why?
|
| Outpatients | 1 | 2001 | 251 | 0.010 |
Why?
|
| Keratin-20 | 1 | 1999 | 8 | 0.010 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2002 | 930 | 0.010 |
Why?
|
| Actins | 1 | 2001 | 313 | 0.010 |
Why?
|
| Mitosis | 1 | 2000 | 191 | 0.010 |
Why?
|
| Time | 1 | 1999 | 93 | 0.010 |
Why?
|
| Interleukin-1 | 1 | 2000 | 131 | 0.010 |
Why?
|
| Enzyme Inhibitors | 1 | 2002 | 564 | 0.010 |
Why?
|
| DNA Damage | 1 | 2002 | 490 | 0.010 |
Why?
|
| Gene Expression Profiling | 1 | 2006 | 1779 | 0.010 |
Why?
|
| Sex Chromosome Aberrations | 1 | 1999 | 61 | 0.010 |
Why?
|
| Antigens, CD | 1 | 2000 | 415 | 0.010 |
Why?
|
| Karyotyping | 1 | 1999 | 313 | 0.010 |
Why?
|
| Janus Kinase 1 | 1 | 1998 | 9 | 0.010 |
Why?
|
| Postmenopause | 1 | 1999 | 139 | 0.010 |
Why?
|
| Animals, Newborn | 1 | 2001 | 1014 | 0.010 |
Why?
|
| Ovarian Follicle | 1 | 1999 | 119 | 0.010 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 1999 | 751 | 0.010 |
Why?
|
| Cystoscopy | 1 | 1998 | 42 | 0.010 |
Why?
|
| Tyrosine | 1 | 1998 | 146 | 0.010 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 1 | 1998 | 92 | 0.010 |
Why?
|
| STAT5 Transcription Factor | 1 | 1998 | 85 | 0.010 |
Why?
|
| Cell Membrane Permeability | 1 | 1997 | 66 | 0.010 |
Why?
|
| Xenopus laevis | 1 | 1997 | 118 | 0.010 |
Why?
|
| Ovarian Neoplasms | 1 | 2001 | 441 | 0.010 |
Why?
|
| Pupa | 1 | 1996 | 22 | 0.010 |
Why?
|
| Consensus Sequence | 1 | 1996 | 53 | 0.010 |
Why?
|
| Enzyme Activation | 1 | 1998 | 581 | 0.010 |
Why?
|
| In Situ Hybridization | 1 | 1997 | 455 | 0.010 |
Why?
|
| Janus Kinase 2 | 1 | 1998 | 131 | 0.010 |
Why?
|
| beta-Galactosidase | 1 | 1996 | 134 | 0.010 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 1997 | 622 | 0.010 |
Why?
|
| Zinc Fingers | 1 | 1996 | 108 | 0.010 |
Why?
|
| Chronic Disease | 1 | 2000 | 1177 | 0.010 |
Why?
|
| Regulatory Sequences, Nucleic Acid | 1 | 1996 | 147 | 0.010 |
Why?
|
| Gestational Age | 1 | 2000 | 1205 | 0.010 |
Why?
|
| Organ Specificity | 1 | 1996 | 396 | 0.010 |
Why?
|
| Infant, Newborn | 1 | 2009 | 8368 | 0.010 |
Why?
|
| Injections, Epidural | 1 | 1995 | 4 | 0.010 |
Why?
|
| Hormone Antagonists | 1 | 1995 | 46 | 0.010 |
Why?
|
| Genes, Reporter | 1 | 1996 | 344 | 0.010 |
Why?
|
| Oocytes | 1 | 1997 | 278 | 0.010 |
Why?
|
| Longitudinal Studies | 1 | 1999 | 1421 | 0.010 |
Why?
|
| Smoking | 1 | 1999 | 894 | 0.010 |
Why?
|
| Polyploidy | 1 | 1994 | 16 | 0.010 |
Why?
|
| Sensitivity and Specificity | 1 | 1999 | 2033 | 0.010 |
Why?
|
| Phosphorylation | 1 | 1998 | 1539 | 0.010 |
Why?
|
| Hypertonic Solutions | 1 | 1994 | 20 | 0.010 |
Why?
|
| Proportional Hazards Models | 1 | 1998 | 1343 | 0.010 |
Why?
|
| Gamma Rays | 1 | 1994 | 41 | 0.010 |
Why?
|
| Osteoporosis | 1 | 1995 | 131 | 0.010 |
Why?
|
| Sequence Homology, Nucleic Acid | 1 | 1994 | 252 | 0.010 |
Why?
|
| Glasgow Coma Scale | 1 | 1994 | 194 | 0.010 |
Why?
|
| Infant | 1 | 2009 | 12776 | 0.010 |
Why?
|
| Gene Amplification | 1 | 1994 | 227 | 0.010 |
Why?
|
| Craniotomy | 1 | 1994 | 99 | 0.010 |
Why?
|
| Urography | 1 | 1993 | 30 | 0.010 |
Why?
|
| Repetitive Sequences, Nucleic Acid | 1 | 1994 | 354 | 0.010 |
Why?
|
| Introns | 1 | 1994 | 283 | 0.010 |
Why?
|
| Receptors, Interleukin-3 | 1 | 1992 | 4 | 0.010 |
Why?
|
| Interleukin-3 | 1 | 1992 | 17 | 0.010 |
Why?
|
| Emergencies | 1 | 1994 | 172 | 0.010 |
Why?
|
| Activities of Daily Living | 1 | 1995 | 402 | 0.010 |
Why?
|
| Kallikrein-Kinin System | 1 | 1992 | 2 | 0.010 |
Why?
|
| Prostaglandins | 1 | 1992 | 39 | 0.010 |
Why?
|
| Bradykinin | 1 | 1992 | 45 | 0.010 |
Why?
|
| DNA Mutational Analysis | 1 | 1994 | 780 | 0.010 |
Why?
|
| Hemodynamics | 1 | 1995 | 800 | 0.010 |
Why?
|
| Chlorophyta | 1 | 1991 | 4 | 0.010 |
Why?
|
| Pituitary Gland, Anterior | 1 | 1991 | 18 | 0.010 |
Why?
|
| Lactates | 1 | 1991 | 73 | 0.010 |
Why?
|
| Food, Fortified | 1 | 1991 | 62 | 0.010 |
Why?
|
| beta Carotene | 1 | 1991 | 36 | 0.010 |
Why?
|
| Fatty Acids, Nonesterified | 1 | 1991 | 113 | 0.010 |
Why?
|
| Glucose Tolerance Test | 1 | 1991 | 199 | 0.010 |
Why?
|
| Manometry | 1 | 1989 | 71 | 0.000 |
Why?
|
| Anti-Bacterial Agents | 1 | 2001 | 2508 | 0.000 |
Why?
|
| Chemistry | 1 | 1988 | 53 | 0.000 |
Why?
|
| Acetates | 1 | 1989 | 73 | 0.000 |
Why?
|
| Chemical Phenomena | 1 | 1988 | 81 | 0.000 |
Why?
|
| Drug Evaluation | 1 | 1988 | 102 | 0.000 |
Why?
|
| Pruritus | 1 | 1988 | 47 | 0.000 |
Why?
|
| Urologic Diseases | 1 | 1988 | 43 | 0.000 |
Why?
|
| Gram-Negative Bacteria | 1 | 1988 | 71 | 0.000 |
Why?
|
| Precancerous Conditions | 1 | 1991 | 276 | 0.000 |
Why?
|
| Genetic Variation | 1 | 1994 | 1520 | 0.000 |
Why?
|
| Blood Glucose | 1 | 1991 | 1084 | 0.000 |
Why?
|
| Skin | 1 | 1989 | 515 | 0.000 |
Why?
|
| Insulin | 1 | 1991 | 1132 | 0.000 |
Why?
|
| Microbial Sensitivity Tests | 1 | 1988 | 822 | 0.000 |
Why?
|
| Bacterial Infections | 1 | 1988 | 319 | 0.000 |
Why?
|
| Liver | 1 | 1991 | 1752 | 0.000 |
Why?
|